Cost-effectiveness of treatment strategies for populations from strongyloidiasis high-risk areas globally who will initiate corticosteroid treatment in the USA
Journal of Travel Medicine · 2024
DOI: 10.1093/jtm/taad054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Travel Medicine, 2024. Verfasst von Heesoo Joo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Global Migration and Quarantine, U.S. Centers for Disease Control and Prevention, Atlanta, GA 30329, USA. Hauptthemen laut MEDLINE: Strongyloidiasis, Cost-Benefit Analysis, Strongyloides stercoralis, Ivermectin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Background
The risk of developing strongyloidiasis hyperinfection syndrome appears to be elevated among individuals who initiate corticosteroid treatment. Presumptive treatment or treatment after screening for populations from Strongyloides stercoralis-endemic areas has been suggested before initiating corticosteroids. However, potential clinical and economic impacts of preventative strategies have not been evaluated.
Methods
Using a decision tree model for a hypothetical cohort of 1000 individuals from S. stercoralis-endemic areas globally initiating corticosteroid treatment, we evaluated the clinical and economic impacts of two interventions, ‘Screen and Treat’ (i.e. screening and ivermectin treatment after a positive test), and ‘Presumptively Treat’, compared to current practice (i.e. ‘No Intervention’). We evaluated the cost-effectiveness (net cost per death averted) of each strategy using broad ranges of pre-intervention prevalence and hospitalization rates for chronic strongyloidiasis patients initiating corticosteroid treatment.
Results
For the baseline parameter estimates, ‘Presumptively Treat’ was cost-effective (i.e. clinically superior with cost per death averted less than a threshold of $10.6 million per life) compared to ‘No Intervention’ ($532 000 per death averted) or ‘Screen and Treat’ ($39 000 per death averted). The two parameters contributing the most uncertainty to the analysis were the hospitalization rate for individuals with chronic strongyloidiasis who initiate corticosteroids (baseline 0.166%) and prevalence of chronic strongyloidiasis (baseline 17.3%) according to a series of one-way sensitivity analyses. For hospitalization rates ≥0.022%, ‘Presumptively Treat’ would remain cost-effective. Similarly, ‘Presumptively Treat’ remained preferred at prevalence rates of ≥4%; ‘Screen and Treat’ was preferred for prevalence between 2 and 4% and ‘No Intervention’ was preferred for prevalence <2%.
Conclusions
The findings support decision-making for interventions for populations from S. stercoralis-endemic areas before initiating corticosteroid treatment. Although some input parameters are highly uncertain and prevalence varies across endemic countries, ‘Presumptively Treat’ would likely be preferred across a range for many populations, given plausible parameters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Global Migration and Quarantine, U.S. Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
- Infectious Disease Section, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN 55417, USA.
- Department of Medicine, Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
- Center for Global Health and Social Responsibility, University of Minnesota, Minneapolis, MN 55455, USA.
Förderung
- Intramural CDC HHS
Zitieren
APA
Joo, H., Maskery, B. A., Alpern, J. D., Weinberg, M., & Stauffer, W. M. (2024). Cost-effectiveness of treatment strategies for populations from strongyloidiasis high-risk areas globally who will initiate corticosteroid treatment in the USA. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taad054
Vancouver
Joo H, Maskery BA, Alpern JD, Weinberg M, Stauffer WM. Cost-effectiveness of treatment strategies for populations from strongyloidiasis high-risk areas globally who will initiate corticosteroid treatment in the USA. Journal of Travel Medicine. 2024. doi:10.1093/jtm/taad054
BibTeX
@article{Joo2024,
author = {Joo, Heesoo and Maskery, Brian A and Alpern, Jonathan D and Weinberg, Michelle and Stauffer, William M},
title = {Cost-effectiveness of treatment strategies for populations from strongyloidiasis high-risk areas globally who will initiate corticosteroid treatment in the USA},
journal = {Journal of Travel Medicine},
year = {2024},
doi = {10.1093/jtm/taad054}
}
EUVIMED